S ystemic lupus erythematosus (SLE)
4 is characterized by increased levels of serum autoantibodies directed against multiple self Ags, including determinants expressed on the surface of lymphocytes (1, 2) . Indeed, it is well established that most patients with SLE develop IgM anti-lymphocyte autoantibodies (ALA) at some point in the course of the disease (1, 2) . The best-characterized ALA are cold-reactive anti-T cell IgM Abs with lymphocytotoxic activity whose serum levels correlate with the degree of global peripheral lymphopenia and disease activity (3) . Yet, warm-reactive IgG ALA have also been reported in SLE (4) . Although ALA are most likely heterogeneous in terms of antigenic reactivity, IgM ALA appear to preferentially recognize different isoforms of CD45, a transmembrane protein tyrosine phosphatase expressed in the surface of both B and T cells that plays a central role in lymphocyte homeostasis (5, 6) .
SLE anti-CD45 Abs have been reported to recognize nonsialylated carbohydrate determinants in the highly O-glycosylated polymorphic domains of CD45 isoforms expressed by T cells (7) (8) (9) . By and large, these Abs appear to preferentially bind T cells, but not B cells, suggesting that they recognize a T cell-specific CD45 glycoform (4, 7, 10, 11 ). Yet, the information summarized above needs to be reconciled with the observation that at least a subset of lupus autoantibodies has the ability to bind B cells possibly by recognizing a B cell-specific CD45 isoform (12) (13) (14) . Such autoantibodies, termed V H 4.34 Abs, owing to their expression of surface Ig encoded by the V H 4.34 gene segment, are intrinsically autoreactive by virtue of their almost universal, and largely L chain-independent, recognition of the N-acetyllactosamine (NAL) antigenic determinant of the I/i blood group Ag (15) (16) (17) . Strikingly, V H 4.34 Abs make up the vast majority of pathogenic IgM anti-i cold agglutinin, and the V H 4.34 gene segment seems to be mandatory for the generation of such autoantibodies (18, 19) . Of note, NAL is also expressed on a 220-kDa CD45 B cell-specific isoform, which has been postulated to represent the antigenic target of V H 4.34 IgM Abs derived either from patients with WiskottAldrich syndrome or monoclonal cold agglutinin disease (13, 14, 20 -22) . However, in these studies, the V H 4.34 Abs used failed to immunoprecipitate CD45, and therefore the actual nature of their antigenic target in B cells remains to be formally established.
Despite the abundance of V H 4.34 B cells in normal individuals, V H 4.34 Abs are virtually undetectable in healthy sera due to strict censoring of V H 4.34 B cells (23, 24) . However, circulating V H 4.34 Abs are highly expressed in patients with SLE in whom they constitute a substantial fraction of anti-DNA Abs and highly correlate with overall disease activity, kidney, and CNS involvement (25) (26) (27) (28) . We have reported that censoring of V H 4.34 B cells in healthy subjects is largely achieved by exclusion from participating in productive germinal center reactions (24) . Our studies also show that this censoring mechanism is faulty in patients with SLE in whom V H 4.34 B cells frequently form mature germinal centers and are abundantly expressed in the IgG memory and plasma cell repertoire (29) . However, the actual antigenic reactivity of V H 4.34 IgG Abs in SLE sera remains to be determined with a recent study suggesting that such Abs may not represent a major B cell-binding species (27) .
In the present study, we have analyzed the contribution of IgG V H 4.34 Abs to the anti-lymphocyte repertoire in SLE and conclusively established the molecular basis for the reactivity of these Abs with human B cells. We demonstrate that V H 4.34 IgG Abs target a developmentally regulated B220-specific glycoform of CD45, and more specifically, an N-linked NAL determinant preferentially expressed on naive B cells. Strikingly, our data also indicate that the reactivity of SLE sera with this CD45 glycoform is dependent on V H 4.34 Abs and can be eliminated by depleting these Abs. To the best of our knowledge, our results also represent the first quantitative analysis of the abundance of V H 4.34 Abs in the SLE IgG repertoire. Our findings indicate that V H 4.34 Abs constitute a large fraction (10 -50%) of all IgG in active SLE patients. The implications of our results regarding the antigenic selection and possible pathogenic roles of these autoantibodies in SLE are discussed.
Materials and Methods

Human samples
Peripheral blood (PBL) and tonsil samples were obtained from healthy donors, according to protocols approved by the University of Rochester Medical Center (URMC) Institutional Review Board. Tonsils were obtained as excess tissue from elective tonsillectomies from otherwise healthy patients aged 2-10 years. Only PBL was obtained from SLE patients. Patients were randomly selected from the URMC Lupus Clinic on the basis of their willingness to participate in the study if they had a clinical diagnosis of SLE, fulfilled Ն4 American College of Rheumatology criteria for the classification of SLE (30, 31) , and had been only treated with antimalarials and/or low-dose prednisone (Ͻ10 mg/day) for at least 4 wk previous to venipuncture. Patients were classified as having nephritis based on the presence of an active urinary sediment, proteinuria Ն1000 mg/24 h, and/or a history of nephritis documented by kidney biopsy.
ELISA for detection of serum V H 4.34-encoded Abs
ELISA plates (Nunc, Naperville, CA) were coated with V H 4.34-specific anti-idiotypic mAb 9G4 (kindly provided by F. Stevenson, Tenovus Research Laboratories, Southampton, U.K.), or its isotype control (rat IgG2a; Sigma-Aldrich, St. Louis, MO), at 2 g/ml and incubated for 1 h at 37°C (32) . Plates were blocked with 2% nonfat dry milk/2% BSA for 1 h at 37°C, and then washed with 0.1% Tween 20 in PBS. Sera were serially diluted in HBSS (Life Technologies, Carlsbad, CA) and incubated for 30 min at 37°C. Plates were washed, then incubated with alkaline phosphatase-conjugated goat anti-human IgG (1/2000 dilution; BioSource International, Camarillo, CA) at 37°C for 1 h. After washing, plates were developed using the pNPP substrate system (Kirkegaard & Perry Laboratories, Gaithersburg, MD), according to manufacturer's instructions, and OD at 405 nm was read on a microplate reader (model 3550-UV; Bio-Rad, Hercules, CA). Serum concentrations were determined using a V H 4.34 IgG standard represented by a V H 4.34 IgG mAb established in our laboratory by EBV immortalization of SLE PBL B cells. V H 4.34 IgG levels were corrected with respect to total serum IgG for all samples analyzed. The amount of total IgG in serum samples was determined by isotype-specific capture ELISA using goat anti-human IgG (5 g/ml; Kirkegaard & Perry Laboratories) as the coating Ab and a human IgG standard (Sigma-Aldrich, St. Louis, MO) for quantitation.
B cell isolation
All protocols were conducted, as previously described, in our laboratory (24) . Briefly, mononuclear cells were isolated from heparinized peripheral blood (PBL) by gradient centrifugation at 4°C using Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). PBL B cells were obtained through magnetic positive selection using CD19 microbeads (MACS; Miltenyi Biotec, Auburn, CA) with a final purity of Ͼ98% CD19 ϩ as determined by FACS. Tonsillar cell suspensions were generated by mincing tissue in RPMI 1640 medium containing 10% FBS (Life Technologies), followed by one round of T cell depletion using 2-aminoethylisothiouronium bromide-SRBC (Colorado Serum, Denver, CO) and FicollPaque centrifugation. The resulting cells (Ͼ97-99% CD19 ϩ ) were used directly for phenotypic analysis via flow cytometry.
Naive and memory B cell isolation
For naive cell purification, 10 8 tonsillar B cells were labeled with anti-CD27 PE for 30 min at 4°C. After removing unbound Abs by washing three times in staining buffer (1ϫ PBS, 1% BSA), cells were resuspended in degassed binding buffer (1ϫ PBS, 2 mM EDTA, 0.5% BSA), incubated for 15 min at 4°C with anti-PE microbeads, and then negatively selected using an anti-CD27 MACS column (Miltenyi Biotec). When necessary, fractions were run over a second column to achieve Ͼ98% purity. The CD27 Ϫ fraction thus obtained was labeled with IgD FITC, washed, incubated with anti-FITC microbeads, and passed over a MACS column for positive selection. To obtain memory B cells, fractions were initially depleted of IgD ϩ cells, followed by magnetic positive selection for CD27 ϩ , as described above. The purity of the naive and memory fractions was verified by FACS.
Multiparameter FACS analysis
Single cell suspensions (10 6 /sample) were labeled at 4°C for 30 min with predetermined optimal concentrations of fluorophore-conjugated mAbs, and pair-matched isotype controls, in combinations outlined in each figure legend. The following Abs were used: anti-CD19 allophycocyanin (SJ25C1), anti-CD27 PE (L128), streptavidin-PerCP, and rat IgG2a FITC (isotype control for 9G4) (BD Biosciences, San Jose, CA); biotinylated anti-IgD and anti-IgD FITC (IA6-2; BD PharMingen, Los Angeles, CA); and anti-CD45R/B220 allophycocyanin (RA3-6B2; eBioscience, San Diego, CA). V H 4.34 Abs were detected with the rat anti-idiotypic mAb 9G4. Control V H 3 Igs were detected with the avian anti-idiotypic mAb LJ26 (kindly provided by G. Silverman, University of California at San Diego, La Jolla, CA) (33) . For indirect staining, cells were washed three times in staining buffer before incubation with secondary Abs. All samples were analyzed via a FACSCalibur flow cytometer using CellQuest software (BD Biosciences). In total, 50,000 -100,000 events, gated for live B cells based on forward and side scattering, were collected for each sample. Statistical significance was assessed using nonparametric Mann-Whitney U test with the GraphPad Prism software (GraphPad, San Diego, CA).
Detection of V H 4.34 Ab binding to B cells in vitro
Tonsillar B cells were incubated in heat-inactivated sera at 4°C for 30 min. Cells were washed three times in staining buffer, labeled with appropriate fluorophore-conjugated mAbs (and isotype-matched controls), then analyzed via FACS. For blocking experiments, sera were preincubated with 50 g of unlabeled 9G4 (or rIgG2a, isotype control) for 60 min at 4°C with constant rocking before binding reactions.
V H 4.34 Ig depletion and purification by affinity chromatography
SLE sera were fractionated by ammonium sulfate (AmSO 4 ) precipitation, dialyzed, and applied to an affinity column of either agarose-9G4 or agarose-rIgG2a isotype control (Aminolink Immobilization Kit; Pierce-Endogen, Rockford, IL). After washing extensively with PBS, bound V H 4.34 Ig was eluted in 0.1 M glycine (pH 2.7). Positive fractions, as determined by absorbance at 280 nm, were pooled, neutralized with 1 M Tris (pH 9.5), and dialyzed against 1ϫ PBS. V H 4.34-specific binding of depleted sera and eluates was determined by incubation and FACS, as previously described.
Immunoprecipitation of CD45
Purified B cell fractions (5 ϫ 10 7 cells/ml) were lysed at room temperature with occasional vortexing in mammalian protection extraction reagent buffer (Pierce-Endogen) supplemented with 150 mM NaCl, 0.1 mM PMSF, and protease inhibitors (Sigma-Aldrich). Extracts were then cleared by ultracentrifugation. Lysates (1 ϫ 10 7 cells/reaction) were precleared with protein A/G-Sepharose (Pierce-Endogen), then incubated with either anti-CD45/leukocyte common Ag (LCA) (F10-89-4), anti-CD45RA (F8-11-13), anti-CD45R/B220 (RA3-6B2), or anti-CD45RO (UCHL1) (Southern Biotechnology Associates, Birmingham, AL), or isotype control Ab for 2 h with constant rotation at 4°C. Protein A/G-Sepharose beads were added, and incubations were continued for another 18 h at 4°C. Immune complexes were washed five times in lysis buffer, resolved by SDS-PAGE on 7% gels, then electroblotted to nitrocellulose membrane (1 h at 100 V). To specifically determine the binding of serum IgG to CD45, blots were probed with the appropriate dilutions of whole sera (either SLE derived or healthy control) or 9G4 affinity column-purified V H 4.34 Ab fractions, followed by goat anti-human IgG HRP (Sigma-Aldrich). Blots were developed using an ECL Plus detection kit (Amersham Pharmacia Biotech) for autoradiography with BIOMAX film (Eastman Kodak, Rochester, NY), according to the manufacturers' instructions. Alternatively, precleared lysates were incubated with either whole sera, V H 4.34-depleted sera, or 9G4 affinity column eluates for 2 h at 4°C. Protein A/G-Sepharose was added, and the incubation continued for 18 h. Immune complexes were resolved and blotted, as described above. Blots were probed with either anti-CD45/ LCA or anti-CD45R/B220, followed by anti-mouse IgG HRP or anti-rat IgG HRP (Southern Biotechnology Associates), respectively, and developed, as previously described.
Glycosidase treatment
Immunoprecipitated CD45R/B220 was eluted from protein A/G beads under denaturing conditions (0.1% SDS, 0.5% 2-ME) by heating at 100°C for 3 min, then digested with either endo-␤-galactosidase (Sigma-Aldrich), N-glycanase, O-glycanase, or neuraminidase (Glyko, Novato, CA) alone, or in combination, according to the manufacturer's instructions. Deglycosylated and control samples (minus enzyme) were resolved by SDS-PAGE on 7% gels and transferred by electroblotting to nitrocellulose membrane. Immunoblotting with purified SLE V H 4.34 Abs was performed, as previously described. Blots were probed with anti-CD45/LCA mAb in parallel to verify glycosidic digestion.
Results
Identification of IgG V H 4.34 Abs in SLE sera
Serum levels of V H 4.34 Abs (whether IgM or IgG) have been consistently characterized in several reports as very low to undetectable in normal donors (23, (25) (26) (27) (28) . In contrast, elevated serum levels of IgG V H 4.34 Abs have been highly associated with global disease activity in patients with SLE and with the presence of lupus nephritis and neuropsychiatric lupus (26 -28) . Therefore, we first sought to identify patients with elevated serum V H 4.34 IgG Ab levels using 9G4 in a capture ELISA. Of 22 SLE patients analyzed, 16 subjects (72%) had significantly elevated Ab titers (defined as values greater than 3 SD over the mean observed in healthy sera). Consistent with previous studies, healthy controls had very low levels of serum IgG V H 4.34 Abs (Fig. 1) . We then classified the SLE patients into high and low V H 4.34 IgG Ab cohorts (SLE high and SLE low , respectively) using an arbitrary cutoff point of 0.5 mg/ml, which represented a 4-fold increase over the normal mean. By this definition, 12 patients (55%) belonged in the SLE high cohort and 10 patients in the SLE low cohort (Fig. 1A) . To assess the relative contribution of V H 4.34 Abs to the SLE IgG Ab repertoire, we also determined the ratio of V H 4.34 IgG to total IgG. As shown in Fig. 1B (27) . Also in keeping with previous reports, this group had significantly higher antidsDNA titers (detected by ELISA, p ϭ 0.02), and lower C3 levels ( p ϭ 0.006) than the V H 4.34 low cohort (data not shown). High serum V H 4.34 Abs also correlated with the presence of nephritis (10 of 12 and 0 of 8, respectively, p ϭ 0.0001). As shown in Table  I, SLE high patients were also characterized by significant lymphopenia affecting the naive B cell subset.
SLE V H 4.34 Abs preferentially bind autologous naive B cells in vivo
We have previously shown that in normal subjects, V H 4.34 B cells represent up to 10% of all naive B cells, but only ϳ1% of memory B cells (24) . Therefore, it is rather remarkable that in V H 4.34 high SLE patients, a large fraction of their naive B cells (mean percentage Ϯ SD: 63.3 Ϯ 39.8) stains positive for the V H 4.34-specific 9G4 Ab when analyzed by FACS directly ex vivo ( Fig. 2A and Table II ). In contrast, a significantly smaller fraction (9.6 Ϯ 8.1%) of memory B cells was 9G4 ϩ in these patients. The corresponding values observed in our V H 4.34 low cohort were indistinguishable from healthy controls, as determined in this study and in our previous studies (Table II) (24) . As opposed to V H 4.34 cells, no significant differences in the relative frequency of control B cells expressing V H 3-encoded Abs were observed between the different cohorts. To determine whether these results reflected the presence of an unlikely high number of V H 4.34 B cells in the SLE repertoire or rather diverse B cells painted by absorbed serum V H 4.34 Abs, we repeated the 9G4-staining experiments after extensive washing in PBS, followed by incubation in complement-inactivated FCS at 37°C for 60 min, a protocol previously used by others to elute cytotrophic Abs (27, 35) . After elution, the number of naive B cells that stained positive with 9G4 returned to values close to those observed in healthy donors and in V H 4.34 low patients (Fig. 2) . These results indicate that in VH4. 34 high SLE patients, the vast majority of 9G4 ϩ naive B cells represent cells bearing exogenously bound V H 4.34 Abs.
SLE V H 4.34 Abs preferentially bind healthy naive B cells in vitro
Ex vivo studies were expanded by determining the ability of SLEderived V H 4.34 Abs to stain normal tonsil B cells in vitro (Fig. 3) with unlabeled 9G4 Ab completely blocked V H 4.34 Ab binding in a dose-dependent fashion (data not shown). As opposed to V H 4.34, the relative frequency of B cells stained with anti-V H 3 Abs was unaffected by incubation with any sera analyzed (Fig. 3, A-D, right  panel) . The later result strongly suggests that V H 3 Abs expressed in SLE sera do not bind B cells and that in contrast, V H 4.34 Abs seem to contribute the majority of anti-B cell Abs in SLE sera. To confirm that V H 4.34 Abs were indeed responsible for the B cell binding observed, V H 4.34 high sera were preabsorbed on 9G4 affinity columns before assaying for B cell binding. In each case, the V H 4.34-depleted fraction was devoid of binding activity, while the V H 4.34-enriched fraction recovered in the eluate possessed the same binding characteristics as the original sera (Fig. 4) . In contrast, fractions absorbed on either rIgG2a (9G4 isotype control) or LJ26 columns showed no loss in binding activity (data not shown).
V H 4 -34 Abs bind specifically to an N-linked carbohydrate moiety of CD45R/B220, a unique glycoform of CD45
Previous studies have suggested that at least some V H 4.34 mAbs may cross-react with an isoform of CD45 expressed on the surface of B cells (21) . Albeit this reactivity was not formally demonstrated, the expression of NAL oligosaccharides in CD45 and the frequent presence of anti-CD45 autoantibodies in SLE sera lend credence to this hypothesis (9, 20, 22) . To identify the antigenic target(s) of anti-B cell V H 4.34 Abs, sera from SLE patients and healthy controls were initially examined by immunoblotting for reactivity to CD45 fractions purified from bulk tonsil B cell lysates by immunoprecipitation using LCA, a pan-CD45 mAb (Fig. 5A) . From the control LCA lane, it is apparent that CD45 expression is quite complex, involving a large group of alternatively spliced and glycosidically modified species ranging in size from 180 to 220 kDa. Consistent with our FACS results, CD45 reactivity was strictly limited to V H 4.34 high sera (Fig. 5A) . All V H 4.34 high sera demonstrated binding to a 220-kDa CD45 species, as determined by probing in parallel with anti-CD45/LCA (Fig. 5A, LCA lane) . This interaction was also confirmed by LCA Western blot following precipitation of CD45 with AmSO 4 -fractionated V H 4.34 high sera (Fig. 5B) . However, consistent with previous reports, individual sera displayed a significant degree of variability with regard to reactivity toward other isoforms of CD45, in particular an isoform at ϳ180 kDa (10, 36) . Because in the experiments depicted in Fig.  5A the final detection step was performed with anti-human IgG Abs, our results establish that SLE V H 4.34 IgG Abs bind B cell-derived CD45.
Strikingly, recognition of the CD45 220-kDa isoform appeared to be solely dependent on the presence of V H 4.34 Abs, as V H 4.34 high sera, depleted of V H 4.34 Abs by prior absorption on 9G4 affinity columns, lost this activity while retaining their ability to bind other species of CD45 (Fig. 6A, lanes 5 and 6) . By contrast, serum fractions purified on either rat IgG2a as an isotype control Ab for 9G4 (Fig. 6A, lane 3) or LJ26 (data not shown) columns were devoid of CD45 reactivity. Purified V H 4.34 Abs were further examined by immunoblotting for reactivity with isoform-specific isolates of CD45. As shown in Fig. 6B , the ϳ220-kDa band detected by V H 4.34 Abs following precipitation by LCA was eliminated by prior extract depletion with either CD45RA or B220 (RA3-6B2) Abs (lanes 4 and 5, respectively), but not a CD45RO-restricted mAb that specifically recognizes the smaller 180-kDa isoform (lane 3). V H 4.34 reactivity was also abolished if extracts were preabsorbed with LCA before precipitation with anti-CD45R/B220, thus confirming that the 220-kDa protein recognized represents a CD45R full-length isoform bearing the B220 epitope (lanes 6 and 7). We further investigated whether V H 4.34 Abs bound to different B cell fractions segregated according to their expression of B220 using a B220 glycoform-specific mAb, RA3-6B2 (37) . As shown in Fig. 7 , V H 4.34 Abs bind to Ͼ90% of B220 ϩ naive B cells, whereas no significant staining of B220 Ϫ B cells was observed. However, V H 4.34 Abs only recognize a rather small fraction (ϳ10%) of B220 ϩ memory B cells. Together, the above experiments strongly suggest that while V H 4.34 Abs recognize a fulllength CD45R isoform that contains the B220 epitope, the determinant recognized by these Abs is distinct from B220 and is not expressed or exposed in memory B cells.
To further characterize the reactive ligand, CD45R/B220 fractions, immunoprecipitated from either naive or memory B cells, were deglycosylated, and the ability of V H 4.34 Abs to bind these modified fractions was examined via immunoblot. Although binding to naive samples was unaffected by O-glycanase, reactivity was completely removed following digestion with N-glycanase, an enzyme, which releases N-linked sugars (Fig. 8A, lanes 5 and 3,  respectively) . Treatment with endo-␤-galactosidase (an enzyme that specifically cleaves the ␤1-4 linkage of NAL) also abolished V H 4.34 recognition (lane 4). This is in accordance with previous reports of V H 4.34 Abs displaying sensitivity to endo-␤-galactosidase (38 subsequent treatment with O-glycanase (Fig. 8C, lanes 1, 2, and 5) .
As it was the case for naive fractions, V H 4.34 binding was completely eliminated by digestion with N-glycanase (Fig. 8C, lane 3) .
Discussion
Anti-lymphocyte Abs are part of the autoantibody repertoire in patients with SLE. It had been previously established that at least some of these Abs are directed against O-linked carbohydrate determinants expressed by CD45 on T cells. It has also been shown that V H 4.34 IgM Abs, whether mAbs derived from individuals or from patients with Wiskott-Aldrich syndrome or polyclonal Abs FIGURE 5. CD45 reactivity of serum IgG derived from SLE patients. A, CD45 was purified from total tonsil B cells by immunoprecipitation with LCA (a human pan-CD45 mAb), and blotted with SLE V H 4.34 high (4 patients), SLE V H 4.34 low (3 patients), or healthy control sera (3 subjects), followed by anti-human IgG-HRP. The LCA lane demonstrates probing of CD45 precipitates with LCA. For B, proteins precipitated with AmSO 4 -fractionated sera were immunoblotted with LCA. Sera derived from the same patients were used for both A and B. , or 9G4 affinity-purified fractions (C). Staining and FACS analysis for V H 4.34 detection were performed, as previously described in Fig. 3 . In each case, histograms depict the frequency of 9G4 cells within the total population or each subset. obtained from SLE sera, frequently possess anti-lymphocyte reactivity (13, 14, 21, 27, 38) . In SLE, in which V H 4.34 Abs are specifically and substantially expanded, these Abs are capable of binding autologous B cells in vivo (27) . Our results confirm and expand such observations and demonstrate that SLE V H 4.34 Abs preferentially target naive B cells defined by a conventional CD19 ϩ , CD27 Ϫ , IgD ϩ surface phenotype (40, 41) . This result is consistent with the observation that V H 4.34 IgM mAbs preferentially recognize IgD ϩ follicular mantle B cells (13) . In our studies, both autologous SLE peripheral blood naive B cells and heterologous healthy tonsil naive B cells were equally targeted by these Abs. This is the first conclusive identification of the antigenic target of anti-lymphocyte V H 4.34 Abs and provides a molecular explanation for their preferential recognition of naive B cells. Previous work had suggested that these Abs might recognize a B cell-restricted isoform of CD45. Such suggestion was based on the observation that B cell binding paralleled the anti-i reactivity typical of IgM V H 4.34 Abs and could be abolished by endo-␤-galactosidase, a treatment that degrades the NAL units present in CD45 (13, 14, 20, 22, 27 ). Yet, the final proof remained elusive as the mAbs used failed to immunoprecipitate this molecule. Using polyclonal SLE V H 4.34 Abs, however, we were able to consistently immunoprecipitate a 220-kDa CD45 species from naive B cells and demonstrate that IgG V H 4.34 Abs strongly bind this antigenic target. Enzymatic treatments designed to modify glycosylation of surface glycoproteins indicate that the differential recognition of CD45 220 kDa in naive vs memory B cells is dependent on the presence in the former cell subset of a CD45 220-kDa glycoform containing an N-linked carbohydrate moiety that is masked in memory B cells by the developmentally regulated addition of sialic acid residues (42) (43) (44) . The chemical nature of the determinant recognized and the fact that 9G4 mAbs block this interaction confirm that the structure recognized is an N-linked carbohydrate epitope structurally similar to the NAL determinant of the i Ag.
CD45 is expressed as a complex set of several isoforms ranging in size from 180 to 220 kDa, which are generated by alternative splicing of exons A, B, and C. Human and murine mature T cells express different CD45 isoforms in a pattern that depends on function, differentiation state, and previous antigenic engagement. Thus, naive T cells express the higher molecular mass isoforms containing the A exon (CD45RA, 205-220 kDa), whereas activated memory T cells express the smaller 180-kDa CD45RO isoform, which contains none of the A, B, and C exons (45) . CD45/ B220 represents a CD45R full-length isoform containing the A, B, and C exons and is specifically defined by the RA3-6B2 Ab (43, 44) . Although the majority of murine B cells express B220, this molecule had been previously thought not to be present on human B cells. This notion, however, has been corrected by a report published during the preparation of this manuscript in which the authors demonstrate that B220 is actually expressed by the majority of human naive B cells and that its expression is down-regulated on CD27
ϩ memory B cells (46) . In this study, we confirm this report and show that CD45/B220 is expressed in Ͼ90% of all human naive B cells, but in only ϳ20% of memory B cells. Furthermore, we show that while V H 4.34 Abs bind all B220 ϩ naive B cells, they only bind ϳ10% of B220 ϩ memory B cells. Together, we postulate that a B220 glycoform is recognized by V H 4.34 Abs present in high abundance in SLE sera and that the corresponding epitope is sterically masked by sialylated carbohydrate chains (43, 44) .
Our data also show that while SLE sera contain a diversity of anti-lymphocyte and anti-CD45 Abs, anti-CD45R/B220 Abs are essentially restricted to the V H 4.34 Ab fraction. This finding indicates that the remarkable V H 4.34 restriction of the anti-I/i response is maintained in SLE and suggests that this Ag or similar Ags may play a significant role in the activation and/or selection of a large fraction of the autoimmune IgG Ab repertoire in SLE (18, 19) . The pathophysiological significance and the pathogenic implications of this observation are underscored by the magnitude of V H 4.34 serum Ab levels illustrated in this study. Indeed, our data provide a first quantitative appraisal of the magnitude of the V H 4.34 IgG Ab response in SLE. As shown in Fig. 1 , V H 4.34 Abs contributed up to 45% of total serum IgG (mean, 21%; range, 9 -45%) in SLE high patients (representing Ͼ50% of all SLE patients analyzed and a large majority of active patients). Along these lines, it is noteworthy that the I/i Ag may be expressed in oxidized apoptotic cells and that B220 is expressed by preapoptotic T cells (43, 47, 48) . These findings may explain our observation that V H 4.34 Abs (both monoclonal and polyclonal) bind apoptotic cells (49) . Given the proposed role of autoantigenbearing apoptotic cells in the pathogenesis of SLE, it is tempting to speculate that apoptotic bodies could contribute to the expansion of V H 4.34 B cells in this disease (50, 51) .
At least a subset of V H 4.34 Abs may also bind DNA, and serum V H 4.34 Abs have been shown to make up a substantial fraction of anti-dsDNA Abs in patients with SLE (52) . Therefore, it is apparent that V H 4.34 Abs could play a role in the disease process through their participation in this pathogenic Ab response (53) . However, it is also plausible that V H 4.34 Abs could exert a pathogenic role through anti-CD45 effects either by enhancing or damping CD45 activity. Indeed, CD45 is a transmembrane phosphotyrosine phosphatase (PTPase) with the ability to modulate Ag receptor-mediated B and T cell responses both positively and negatively through its conventional PTPase activity and a recently described Janus kinase phosphatase activity (54) . It has been proposed that the activity of CD45 may be dependent on the balance between monomeric and dimeric forms because dimerization results in inhibition of the PTPase activity of the CD45 cytoplasmic domain and negative regulation of Ag receptor signaling. In turn, the interaction between the extracellular domains of the different CD45 isoforms may determine the extent of homodimerization with the larger isoforms such as B220 being less prone to dimerize (55) . It is therefore conceivable that anti-CD45 Abs could interfere with the dimerization process and consequently enhance CD45 function. As demonstrated by the wedge mutation model, unabated CD45 activity may result in polyclonal T and B cell activation and severe autoimmune nephritis with autoantibody production (56, 57) . Should V H 4.34 anti-CD45 Abs indeed result in increased CD45 activity, this effect could also help explain the expansion of TCR ␣␤ ϩ , CD4/CD8 double-negative T cells observed in SLE because these cells have been shown to express the B220 Ag (43, 58) . Conversely, V H 4.34 Abs could facilitate cross-linking of the larger CD45 isoforms, thereby enhancing dimerization and silencing CD45 signaling. This effect could also have pathogenic consequences, as demonstrated in murine models of B cell tolerance in which the absence of CD45 activity promotes positive selection and expansion of autoreactive B cells (59) .
The reactivity of V H 4.34 Abs and the correlation with lower naive B cell levels described in this work (Table II) suggest that these Abs could also contribute to the naive B cell lymphopenia observed in patients with active SLE (34) . Naive lymphopenia could be induced by V H 4.34 Abs whether through their reported lymphocytotoxic activity or by alternative mechanisms (38, 60) . Thus, while costimulatory signaling through the Ag receptor and CD45, in particular B220, is essential both for B cell activation and proliferation, ligation of CD45 alone promotes apoptosis of both T and B lymphocytes (61) (62) (63) (64) . Therefore, V H 4.34 Abs could induce apoptosis of virgin naive B cells upon ligation of CD45 alone while promoting activation and expansion of autoreactive naive B cells actively costimulated by self Ag through the B cell receptor. In turn, lymphocyte apoptosis induced by V H 4.34 Abs would contribute to the availability of exposed intracellular autoantigens that could in turn amplify the autoimmune response possibly through the induction of IFN-␣ production by PBMC. This mechanism would be consistent with the recently reported ability of lupus IgG-apoptotic cell complexes to activate IFN-␣-producing cells, a phenomenon that could bear significant pathogenic potential in SLE, and the ability of IFN-␣ to induce B cell lymphopenia (51, (65) (66) (67) . It is also plausible that anti-CD45 V H 4.34 Abs could contribute to naive lymphopenia by inducing naive B cell differentiation and isotype switch, as previously postulated by others on the basis of in vitro experiments (21, 68) . This mechanism could also help explain the expansion of peripheral blood plasmablasts observed in patients with active SLE (34, 69) .
Additional studies, currently underway in our laboratory, will be required to dissect the mechanisms and the actual consequences of the overexpression of V H 4.34 Abs in SLE.
